바로가기메뉴

본문 바로가기 주메뉴 바로가기

Tuberculosis & Respiratory Diseases

Article Contents

Prev Next
e-Submission

Vol.74 No.6
Citation Share

A Case of Isolated Pulmonary Mucormycosis in an Immunocompetent Host

Tuberculosis & Respiratory Diseases / Tuberculosis & Respiratory Diseases,
2013, v.74 no.6, pp.269-273
Jung Su Lee (University of Ulsan College of Medicine)
Ho Cheol Kim (University of Ulsan College of Medicine)
Sang Woo Park (University of Ulsan College of Medicine)
Hoon Sub So (University of Ulsan College of Medicine)
Chang Yun Woo (University of Ulsan College of Medicine)
Jong Han Choi (University of Ulsan College of Medicine)
Se Jin Kim (The Armed Forced Capital Hospital)

Jung, S. L. , Ho, C. K. , Sang, W. P. , Hoon, S. S. , Chang, Y. W. , Jong, H. C. , Se, J. K. , & (2013). A Case of Isolated Pulmonary Mucormycosis in an Immunocompetent Host. Tuberculosis & Respiratory Diseases, 74(6), 269-273.
  • Downloaded
  • Viewed
PDF Download

Abstract

Mucormycosis is a rare fungal disease that holds a fatal opportunistic fungal infection in diabetes mellitus, hematological malignancy, and immunocompromised host. Isolated pulmonary mucormycosis is extremely rare. Optimal therapy is a combined medical-surgical approach and a management of the patient's underlying disease. Herein, we report a case-study of isolated pulmonary mucormycosis which was being presented as multiple lung nodules in a patient with no underlying risk factors. Considering that the patient had poor pulmonary functions, we treated him with only antifungal agent rather than a combined medical-surgical approach. After treatment with antifungal agent for six months, the nodules of pulmonary mucormycosis were improved with the prominent reductions of size on the computed tomography.

keywords
Mucormycosis, Lung, Immunocompetence, Posaconazole

Reference

1.

Butala A, Shah B, Cho YT, Schmidt MF. Isolated pulmonary mucormycosis in an apparently normal host: a case report. J Natl Med Assoc 1995;87:572-4.

2.

Ibrahim AS, Spellberg B, Walsh TJ, Kontoyiannis DP. Pathogenesis of mucormycosis. Clin Infect Dis 2012;54 Suppl 1:S16-22.

3.

Petrikkos G, Skiada A, Lortholary O, Roilides E, Walsh TJ, Kontoyiannis DP. Epidemiology and clinical manifestations of mucormycosis. Clin Infect Dis 2012;54 Suppl 1:S23-34.

4.

Kim TJ, Park CY, Jin YG, Park KE, Her KM, Kim YH, et al. A case of pulmonary mucormycosis associated uncontrolled diabetes mellitus. Korean J Med 1997; 53(Suppl 3):S792-6.

5.

Lee SJ, Yoon SJ, Kim EJ, Cha SI, Park JY, Jung TH, et al. A case of pulmonary mucormycosis complicated by pneumomediastinum and subcutaneous emphysema after chemotherapy in a patient with small cell lung cancer. Korean J Med 2007;72:551-7.

6.

Pagano L, Offidani M, Fianchi L, Nosari A, Candoni A, Piccardi M, et al. Mucormycosis in hematologic patients. Haematologica 2004;89:207-14.

7.

Cho YJ, Kang MH, Kim HS, Jeong YY, Jang IS, Kim HC, et al. A case of angio-invasive pulmonary mucormycosis with uncontrolled diabetes mellitus. Tuberc Respir Dis 2008;64:451-5.

8.

Spellberg B, Kontoyiannis DP, Fredricks D, Morris MI, Perfect JR, Chin-Hong PV, et al. Risk factors for mortality in patients with mucormycosis. Med Mycol 2012;50: 611-8.

9.

Hamilos G, Samonis G, Kontoyiannis DP. Pulmonary mucormycosis. Semin Respir Crit Care Med 2011;32: 693-702.

Tuberculosis & Respiratory Diseases

e-Submission OA Policy